These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 16531785)
1. Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. Zoccali C J Hypertens; 2006 Apr; 24(4):611-9. PubMed ID: 16531785 [TBL] [Abstract][Full Text] [Related]
2. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? Kielstein JT; Zoccali C Am J Kidney Dis; 2005 Aug; 46(2):186-202. PubMed ID: 16112037 [TBL] [Abstract][Full Text] [Related]
3. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Nanayakkara PW; Teerlink T; Stehouwer CD; Allajar D; Spijkerman A; Schalkwijk C; ter Wee PM; van Guldener C Kidney Int; 2005 Nov; 68(5):2230-6. PubMed ID: 16221223 [TBL] [Abstract][Full Text] [Related]
4. Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients. Kumagai H; Sakurai M; Takita T; Maruyama Y; Uno S; Ikegaya N; Kato A; Hishida A Am J Kidney Dis; 2006 Nov; 48(5):797-805. PubMed ID: 17059999 [TBL] [Abstract][Full Text] [Related]
5. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases. Böger RH; Bode-Böger SM Semin Thromb Hemost; 2000; 26(5):539-45. PubMed ID: 11129410 [TBL] [Abstract][Full Text] [Related]
6. Asymmetric dimethylarginine: a cardiovascular risk factor in renal disease? Fliser D; Kielstein JT; Haller H; Bode-Böger SM Kidney Int Suppl; 2003 May; (84):S37-40. PubMed ID: 12694305 [TBL] [Abstract][Full Text] [Related]
7. The emerging role of symmetric dimethylarginine in vascular disease. Mangoni AA Adv Clin Chem; 2009; 48():73-94. PubMed ID: 19803415 [TBL] [Abstract][Full Text] [Related]
8. Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease. Zoccali C Blood Purif; 2002; 20(5):469-72. PubMed ID: 12207095 [TBL] [Abstract][Full Text] [Related]
9. Reduced renal plasma clearance does not explain increased plasma asymmetric dimethylarginine in hypertensive subjects with mild to moderate renal insufficiency. Ronden RA; Houben AJ; Teerlink T; Bakker JA; Bierau J; Stehouwer CD; De Leeuw PW; Kroon AA Am J Physiol Renal Physiol; 2012 Jul; 303(1):F149-56. PubMed ID: 22552932 [TBL] [Abstract][Full Text] [Related]
10. The endothelium as a target in renal diseases. Zoccali C J Nephrol; 2007; 20 Suppl 12():S39-44. PubMed ID: 18050141 [TBL] [Abstract][Full Text] [Related]
11. [Asymmetric dimethylarginine as cardiovascular risk factor]. Galán A; Formiguera X; Rey-Joly C Med Clin (Barc); 2008 Sep; 131(7):271-5. PubMed ID: 18775219 [TBL] [Abstract][Full Text] [Related]
12. Asymmetric dimethylarginine plasma concentrations and L-arginine/asymmetric dimethylarginine ratio in patients with slow coronary flow. Selcuk MT; Selcuk H; Temizhan A; Maden O; Ulupinar H; Baysal E; Ozeke O; Sasmaz A Coron Artery Dis; 2007 Nov; 18(7):545-51. PubMed ID: 17925608 [TBL] [Abstract][Full Text] [Related]
13. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Krzyzanowska K; Mittermayer F; Wolzt M; Schernthaner G Diabetes Care; 2007 Jul; 30(7):1834-9. PubMed ID: 17456842 [TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethylarginine: a novel cardiovascular risk factor in end-stage renal disease. Alsagaff MY; Thaha M; Aminuddin M; Yogiarto RM; Yogiantoro M; Tomino Y J Int Med Res; 2012; 40(1):340-9. PubMed ID: 22429374 [TBL] [Abstract][Full Text] [Related]
15. Association of asymmetric dimethylarginine and endothelial dysfunction. Böger RH Clin Chem Lab Med; 2003 Nov; 41(11):1467-72. PubMed ID: 14656027 [TBL] [Abstract][Full Text] [Related]
17. Clinical implications of elevated asymmetric dimethylarginine in chronic kidney disease and end-stage renal disease. Mallamaci F; Zoccali C J Ren Nutr; 2009 Jan; 19(1):25-8. PubMed ID: 19121766 [TBL] [Abstract][Full Text] [Related]
18. Arginine, dimethylated arginine and homoarginine in relation to cardiovascular risk in patients with moderate chronic kidney disease. Hov GG; Aasarød KI; Sagen E; Åsberg A Clin Biochem; 2015 Jul; 48(10-11):646-51. PubMed ID: 25828044 [TBL] [Abstract][Full Text] [Related]
19. Asymmetric dimethylarginine and all-cause mortality: a systematic review and meta-analysis. Zhou S; Zhu Q; Li X; Chen C; Liu J; Ye Y; Ruan Y; Hei Z Sci Rep; 2017 Mar; 7():44692. PubMed ID: 28294182 [TBL] [Abstract][Full Text] [Related]
20. Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease. van Guldener C; Nanayakkara PW; Stehouwer CD Clin Chem Lab Med; 2007; 45(12):1683-7. PubMed ID: 17937610 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]